Pharmacokinetics of fluorescent polyporphyrin Photofrin II in normal rat tissue and rat bladder tumor.

GSF-Zentrales Laserlaboratorium, Neuherberg, Fed. Rep. Germany.
Photochemistry and Photobiology (Impact Factor: 2.68). 05/1992; 55(4):569-74. DOI: 10.1111/j.1751-1097.1992.tb04279.x
Source: PubMed

ABSTRACT The transient behavior of the molecular components responsible for fluorescence emission of the photosensitizing polyporphyrin Photofrin II has been studied quantitatively in the liver, small intestines, bladder and muscles of rats. Relative concentrations of the substance were determined fluorometrically in vivo using a Kr(+)-laser (wavelength = 406.7 nm) and a mercury arc lamp (wavelength = 405 or 550 nm) for fluorescence excitation of Photofrin II. Fluorescence was detected at the maxima of the emission bands, at 630 or 690 nm. The results of the experiments show that Photofrin II can be clearly detected by its fluorescence in all the organs investigated from 3 h up to at least 28 days after systemic application of the substance. Within this investigational period the fluorescing components of Photofrin II are released continuously from the organs. In all the tissues examined, an initial decrease with time constants between 2 and 42 h followed by a slow decay with time constants between about 300 and 600 h can be observed. In addition the pharmacokinetics of the fluorescent components of Photofrin II in chemically induced rat bladder tumors with different stages of malignancy were compared to healthy rat bladder tissue. In a time range of 2-10 days after intravenous injection Photofrin II shows a fluorescence 2-5 times brighter in rat bladder tumors than in healthy bladder tissue.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Visualization of early stage bladder cancer is considerably improved using Delta-Aminolevulinic acid (ALA) as tumor marking agent. This is due to an intracellular accumulation of fluorescing Protoporphyrin IX in tissue following intravesical installation of ALA in a pH-neutral solution.
    Proceedings of SPIE - The International Society for Optical Engineering 01/1994; DOI:10.1117/12.166812 · 0.20 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND Photodynamic therapy (PDT) for cancer patients has developed into an important new clinical treatment modality in the past 25 years. PDT involves administration of a tumor-localizing photosensitizer or photosensitizer prodrug (5-aminolevulinic acid [ALA], a precursor in the heme biosynthetic pathway) and the subsequent activation of the photosensitizer by light. Although several photosensitizers other than ALA-derived protoporphyrin IX (PpIX) have been used in clinical PDT, ALA-based PDT has been the most active area of clinical PDT research during the past 5 years. Studies have shown that a higher accumulation of ALA-derived PpIX in rapidly proliferating cells may provide a biologic rationale for clinical use of ALA-based PDT and diagnosis. However, no review updating the clinical data has appeared so far.METHODSA review of recently published data on clinical ALA-based PDT and diagnosis was conducted.RESULTSSeveral individual studies in which patients with primary nonmelanoma cutaneous tumors received topical ALA-based PDT have reported promising results, including outstanding cosmetic results. However, the modality with present protocols does not, in general, appear to be superior to conventional therapies with respect to initial complete response rates and long term recurrence rates, particularly in the treatment of nodular skin tumors. Topical ALA-PDT does have the following advantages over conventional treatments: it is noninvasive; it produces excellent cosmetic results; it is well tolerated by patients; it can be used to treat multiple superficial lesions in short treatment sessions; it can be applied to patients who refuse surgery or have pacemakers and bleeding tendency; it can be used to treat lesions in specific locations, such as the oral mucosa or the genital area; it can be used as a palliative treatment; and it can be applied repeatedly without cumulative toxicity. Topical ALA-PDT also has potential as a treatment for nonneoplastic skin diseases. Systemic administration of ALA does not seem to be severely toxic, but the advantage of using this approach for PDT of superficial lesions of internal hollow organs is still uncertain. The ALA-derived porphyrin fluorescence technique would be useful in the diagnosis of superficial lesions of internal hollow organs.CONCLUSIONS Promising results of ALA-based clinical PDT and diagnosis have been obtained. The modality has advantages over conventional treatments. However, some improvements need to be made, such as optimization of parameters of ALA-based PDT and diagnosis; increased tumor selectivity of ALA-derived PpIX; better understanding of light distribution in tissue; improvement of light dosimetry procedure; and development of simpler, cheaper, and more efficient light delivery systems. Cancer 1997; 79:2282-308. © 1997 American Cancer Society.
    Cancer 06/1997; 79(12):2282 - 2308. DOI:10.1002/(SICI)1097-0142(19970615)79:12<2282::AID-CNCR2>3.0.CO;2-O · 4.90 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In clinical photochemotherapy, irradiation is delayed by a few days with respect to sensitizer injection in order to enhance the specificity of action. However, there are animal experiments which, above all, require a strong response; this is expected to occur if the delay time is much shorter. To assess the influence of the delay time, lesions were produced in rat ears using haematoporphyrin derivative and green light, and characterized by a scoring system. It was found that, starting from the shortest experimentally accessible value (8 min), the intensity of lesions decreases with increasing delay time (by a factor of 2 in 90 min). This result suggests that the lesions are induced by circulating sensitizer. Dose fractionation, performed 97 min after injection, enhances the response (p
    Lasers in Medical Science 03/1996; 11(1):31-36. DOI:10.1007/BF02161290 · 2.42 Impact Factor